Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
Search insider filingsAll Congress filings
MORE TOOLS
WatchlistGold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeSearch insider filingsAll Congress filings
More research tools
ExploreGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View ORKA insider activity ↗

ORKAOruka Therapeutics, Inc.

THE LATEST REPORTED YEAR

The company reported a loss.

$105.43M net loss for the year ended December 31, 2025. These are reported results, not a forecast or a stock recommendation.

Revenue$0Year ended December 31, 2023
Profit or loss-$105.43MYear ended December 31, 2025
Cash from the business-$88.21MYear ended December 31, 2025
Total assets$1.14BAs of June 30, 2026
Total liabilities$24.85MAs of June 30, 2026
Cash & equivalents$268.47MAs of June 30, 2026
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$0
2016-12
$0
2017-12
$0
2018-12
$0
2019-12
$0
2020-12
$0
2021-12
$0
2022-12
$0
2023-12

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
January 1, 2023 – December 31, 2023$0February 1, 202410-K ↗
January 1, 2022 – December 31, 2022$0February 24, 202310-K ↗
January 1, 2021 – December 31, 2021$0March 14, 202210-K ↗
January 1, 2020 – December 31, 2020$0March 18, 202110-K ↗
January 1, 2019 – December 31, 2019$0February 18, 202010-K ↗
January 1, 2018 – December 31, 2018$0February 27, 201910-K ↗
January 1, 2017 – December 31, 2017$0March 22, 201810-K ↗
January 1, 2016 – December 31, 2016$0March 21, 201710-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:Revenues · Retrieved October 11, 2026

Response SHA-256: 3e23b48bd43d48690cc2da8767bd994ea7ae37e724c61a9cefa6f2950dc21518

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.